Ces Urol X:X | DOI: 10.48095/cccu2025017

Evaluation of oncological outcomes using prognostic models in patients operated on for renal cancer – experience from a single center

Marek Kašík, Michal Fedorko
Urologická klinika LF MU a FN Brno

Major statement: This paper aims to evaluate the outcomes of patients who underwent surgical treatment of renal cell carcinoma at the Department of Urology of the University Hospital Brno between 2014 and 2022 using the prognostic models.Objectives of the study: The aim of this study was to evaluate the cohort of patients with surgical treatment of renal cell carcinoma at our institution with regard to prognostic factors using the Leibovich and GRANT prognostic models.

Patients and methods: A retrospective evaluation was performed of baseline data of patients who underwent radical or partial nephrectomy at the Department of Urology, University Hospital Brno between 2014 and 2022. Patients were stratified into prognostic groups based on clinical and pathological characteristics included in commonly used prognostic models (Leibovich 2003 and GRANT score). Five-year progression-free survival was calculated for individual risk groups. Surgical complications were classified based on the need for surgical intervention or patient mortality, corresponding to Clavien-Dindo grade 3-5.

Results: Between 2014 and 2022, 482 patients with suspected renal tumor were operated on at our institution, of whom 312 were men (64.7%) and 170 were women (35.3%). In definitive histology, malignant findings were confirmed in 424 patients (87.9%), 58 findings were histologically benign (12.1%). Recurrence occurred in 35 patients with renal carcinoma, which corresponds to 8.3% of cases with a median interval of 33 months from surgery. The 5-year progression-free survival for the low, intermediate and high risk group according to the Leibovich model was 94.8; 89.6 and 63.2%, respectively. The 5-year progression-free survival according to the GRANT model was 94.1; 95.0 and 73.6% in the case of zero, one and two factors present, respectively.

Conclusion: Our analysis confirms the importance of using established prognostic models for renal cell carcinoma, such as the Leibovich and GRANT scores, in assessing the risk of recurrence and overall survival after surgical treatment. Both scoring systems have demonstrated their ability to differentiate between patients with favorable and unfavorable prognosis.

Keywords: partial nephrectomy – prognostic model – radical nephrectomy – renal cell carcinoma – risk factors

Received: May 15, 2025; Revised: July 2, 2025; Accepted: July 14, 2025; Prepublished online: August 21, 2025 


References

  1. LiteraturaFerlay J, Ervik M, Lam F et al. Global Cancer Observatory: Cancer Today (version 1) [online]. Lyon: International Agency for Research on Cancer 2024. Dostupné z: https://gco.iarc.who.int/today.
  2. Krejčí D, Mužík J, Šnábl I et al. Portál epidemiologie novotvarů v ČR [online]. Brno: Masarykova univerzita 2024. Dostupné z: https://www.svod.cz.
  3. Bex A, Albiges L, Bedke J et al. EAU Guidelines on Renal Cancer. Edn. presented at the EAU Congress, Madrid 2025. Arnhem: EAU Guidelines Office 2025.
  4. Čechová M, Chocholatý M, Babjuk M et al. Prognostické faktory renálního karcinomu. Rozhl Chir 2022; 101(10): 469-477. doi: 10.33699/PIS.2022.101.10.469-477. Go to original source... Go to PubMed...
  5. Kašík M, Fedorko M. Prognostické faktory renálního karcinomu. Ces Urol 2023; 27(3): 139-150. doi: 10.48095/cccu2023021. Go to original source...
  6. Leibovich BC, Blute ML, Cheville JC et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a strat- ification tool for prospective clinical trials. Cancer 2003; 97(7): 1663-1671. doi: 10.1002/cncr.11234. Go to original source... Go to PubMed...
  7. Buti S, Puligandla M, Bersanelli M et al. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. Ann Oncol 2017; 28(11): 2747-2753. doi: 10.1093/annonc/mdx492. Go to original source... Go to PubMed...
  8. Pichler M, Hutterer GC, Chromecki TF et al. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. J Urol 2011; 186(5): 1773-1778. doi: 10.1016/j.juro.2011.07.034. Go to original source... Go to PubMed...
  9. Lee HJ, Lee A, Huang HH et al. External validation of the updated Leibovich prognostic models for clear cell and papillary renal cell carcinoma in an Asian population. Urol Oncol 2019; 37(6): 356.e9-356.e18. doi: 10.1016/j.urolonc.2019.02.014. Go to original source... Go to PubMed...
  10. Choueiri TK, Tomczak P, Park SH et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med 2024; 390(14): 1359-1371. doi: 10.1056/NEJMoa2312695. Go to original source... Go to PubMed...
  11. Leibovich BC, Lohse CM, Cheville JC et al. Predicting oncologic outcomes in renal cell carcinoma after surgery. Eur Urol 2018; 73(5): 772-780. doi: 10.1016/j.eururo.2018.01.005. Go to original source... Go to PubMed...
  12. Rosielo G, Larcher A, Fallara G et al. Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma. Urol Oncol 2022; 40(6): 271.e19-271.e27. doi: 10.1016/j.urolonc.2021.12.010. Go to original source... Go to PubMed...
  13. Usher Smith JA, Li L, Roberts L et al. Risk models for recurrence and survival after kidney cancer: a systematic review. BJU Int 2022; 130(5): 562-579. doi: 10.1111/bju.15673. Go to original source... Go to PubMed...





Web časopisu Česká urologie je určen pouze pro lékaře a odborníky
z oblasti medicíny nebo farmacie.



Beru na vědomí, že informace zveřejněné na těchto stránkách
nejsou určeny pro laickou veřejnost.



Odejít Vstoupit